Once phosphorylated, MDM2 recruits UBE2M to inactivate p53 by neddylation, making the inhibition of UBE2M-MDM2 interactions a promising strategy for cancer treatment in wild-type p53 cells [65]. Here, MDM2 is linked to cancer.